TALK KEYWORD INDEX
This page contains an index consisting of author-provided keywords.
1 | |
1. HLA-DPB1 | |
1. PK -Punjabi Khatri | |
1000 genomes project | |
12/12 HLA | |
2 | |
2. KB-Kashmiri Brahmins | |
2. T-cell Epitope | |
3 | |
3' UTR | |
3. HLA-DP expression | |
3. SCARS- Severe cutaneous acute drug reactions | |
4 | |
4-field resolution | |
4. Graft-versus-Host Disease | |
4th field resolution | |
5 | |
5' UTR | |
9 | |
9/10 unrelated hematopoietic cell transplantation | |
A | |
A*11:01:01:01 | |
Abacavir | |
ABMR | |
Acceptable mismatch program | |
Accurate HLA typing | |
ACE1 | |
activating KIR receptors | |
acute graft-versus-host disease | |
Acute Myeloid Leukaemia | |
acute myeloid leukemia | |
acute rejection | |
ADCC | |
Address | |
Adoptive cell therapy | |
Adoptive immunotherapy | |
Adult Patients | |
Affinity | |
Africa | |
Age | |
allele | |
allele frequencies | |
allele frequency | |
Allele imputation | |
alleles | |
allelic diversity | |
allelic typing | |
allo-HSCT | |
Allocation | |
allogeneic | |
allogeneic hematopoietic cell transplantation | |
allogeneic hematopoietic stem cell transplantation | |
Allogeneic stem cell transplantation | |
Allograft Failure | |
alloimmune response | |
alloimmunization | |
allopeptides | |
Alloreactivity | |
ALS | |
Alternative splicing | |
amino acid substitutions | |
AML | |
Analysis | |
Anthony Nolan | |
Anthropology | |
anti HLA antibodies | |
anti-HLA | |
anti-HLA alloantibodies | |
anti-HLA antibodies | |
Anti-HLA antibody | |
Anti-HMGCR | |
anti-inflammatory cytokines | |
anti-SARS-CoV-2 antibody | |
anti-SARS-CoV-2 vaccination | |
Anti-TNF drugs | |
Antibodies | |
Antibodies against SARS-CoV-2 | |
Antibody | |
antibody affinity | |
antibody concentration | |
antibody verification | |
Antibody Verified-Eplet Mismatch | |
Antibody-dependent cellular cytotoxicity | |
Antibody-mediated rejection | |
antigen binding sites | |
Antigen presentation | |
antigens | |
antitumoral surveillance | |
APRIL | |
Armenian population | |
Ashkenazi | |
Asia | |
assay | |
association | |
Association studies | |
association study | |
autoencoder (AE) | |
autoimmune | |
autoimmune comorbidities | |
autoimmunity | |
autologous metastases | |
Automation | |
Avacavir binding capacity | |
Award | |
Awards | |
B | |
B cells | |
B*52:01:01:02 | |
B-cell | |
BAFF system | |
Balancing selection | |
Barcoded adapters | |
Barcoded primers | |
Be The Match Mexico | |
Best | |
Best Abstracts | |
Big data | |
binding analysis | |
Binding repertoire | |
biobank | |
BIOETHICS | |
bioinformatic tools | |
Bioinformatics | |
Biomarker | |
bladder cancer | |
bladder tumor | |
blasts | |
blood chimerism | |
blood group | |
BMI | |
Bodmer | |
bone marrow donors | |
brain-homing | |
Brazilian population | |
Breakthrough infections | |
breast cancer | |
BSG | |
Buccal swab | |
Bulgarians | |
Bw4 | |
C | |
C*12:02:02:01 | |
C3d assay | |
cancer | |
CAR-T cells | |
Cardiac allograft vasculopathy | |
CD147 | |
CD16 | |
CD226 | |
CD4+ T cell immunity | |
CD4-T cells | |
CD8 T cells | |
CD8+ T lymphocytes | |
CD8-T cells | |
CDC | |
CDR3 | |
celiac disease | |
Cell atlas | |
Cell Culture | |
Cell lines | |
Cell therapy | |
cell-free circulating DNA | |
cellular therapy | |
Ceppellini | |
cfDNA | |
Childhood acute leukemia | |
Chimeric antigen receptor | |
Chimeric HLA Antigen Receptor T cells | |
chimerism | |
Chimerism analysis | |
Chimerism monitoring | |
chimerism testing | |
Chimpanzees | |
Chromosome 19 | |
Chronic hepatitis B | |
Chronic Intervillositis of Unknown Etiology | |
Chronic lymphocytic leukemia | |
Chronic organ rejection | |
chronic rejection | |
circulating DSA | |
Circulating T follicular helper cells | |
class I new alleles | |
Class I non-classical HLA genes | |
Class I non-HLA genes | |
Class Ib typing | |
Clinical | |
clinical outcome | |
CLL | |
Closing | |
Cloud | |
CMV matching | |
coevolution | |
Colorectal cancer | |
Colton | |
Common and Well Documented Allele | |
Comparative primate genetics | |
Complement component 4 | |
Computational biology | |
Convalescent plasma | |
Copy number | |
core" alleles | |
Corona | |
cost-effective | |
COVID 19 | |
COVID-19 | |
COVID-19 convalescent plasma donors | |
COVID-19 severity | |
COVID-19 vaccination | |
COVID19 | |
CRISPR Cas13 | |
crossing over | |
Crossmatch | |
Crossmatching | |
culturing | |
cutoff | |
Cytokine | |
cytokine storm | |
Cytokines | |
cytomegalovirus | |
Cytomegalovirus (CMV) | |
cytotoxicity | |
Czechia | |
D | |
Data analysis | |
Data visualization | |
Database | |
dd-cfDNA | |
ddPCR | |
De novo DSA | |
DEAV/GGPM polymorphism | |
Deceased Donor Typing | |
deep learning | |
Deletion | |
Denatured HLA | |
desensitization | |
Diego | |
differentiation | |
Digital PCR | |
diploid genotype phasing | |
disease association | |
disease severity | |
Diversity | |
dizygotic twin couples | |
DLBCL | |
DNA | |
Donor rs2204985 | |
donor search | |
Donor selection | |
donor-specific antibodies | |
Donor-specific HLA antibodies | |
donors | |
DPB1 | |
DR-panreactivity | |
droplet digital PCR | |
Drug metabolism | |
DSA | |
DSA - Donor Specific Antibody | |
DSA-Donor Specific Antibodies | |
Duffy | |
E | |
Easy Sep | |
EBV-specific T cell | |
EDTA treatment | |
EFI | |
Eiptope Analysis | |
ELISPOT | |
elucidate asterisks in CDS sequences | |
EM-algorithm | |
EMMA | |
endothelial antigens | |
Endothelial permeability | |
Enrichment | |
Epitope | |
epitope specificity | |
epitope-matching | |
Epitopes | |
Eplet | |
eplet mismatch | |
Eplet Verification | |
Eplets | |
Epstein-Barr virus | |
EPT | |
EQA | |
Equality | |
evaluation methods | |
Event Free Survival | |
Evolution | |
Evolutionairy stability | |
Ex vivo Kidney Perfusion | |
Expansion | |
expectation-maximization algorithm | |
expression | |
Expression levels | |
extended MHC haplotypes | |
External proficiency testing | |
External quality assessment | |
Extracorporeal photopheresis | |
Extraction | |
Ezer Mizion Registry | |
F | |
FAIR principles | |
Families | |
fast | |
FCGR3A | |
FCXM | |
Fibrobrast associated protein (FAP) expression | |
Flow Cytometry | |
Flow cytometry crossmatch | |
FRENCH LEGAL FRAMEWORK | |
FREQUENCIES | |
frequency | |
Friends To Marrow | |
full length sequencing | |
Full-gene sequencing | |
Fulllength genomic DNA analysis | |
Functional diversity | |
G | |
Gamma-delta T cell | |
gendx | |
Gene copy number | |
gene duplication | |
gene expression | |
Gene linkage disequilibrium | |
genes | |
Genetic Distance | |
Genetic diversity | |
genetic polymorphism | |
Genetic polymorphisms | |
Genetic risk | |
Genetics | |
genome reference | |
Genome SNP | |
Genome-wide mismatch | |
GENOMIC MEDICINE | |
Genomic sequencing | |
Genomics | |
Genotype | |
Genotypes | |
Genotyping | |
Geographic distances | |
Gerbich | |
Global analysis | |
graft failure | |
Graft rejection | |
Graft survival | |
graft-versus-host | |
graft-versus-host disease | |
graft-versus-leukemia | |
GRIMM | |
Gut | |
GVHD | |
H | |
haaematopietic | |
Haematopoietic stem cell transplant | |
Haematopoietic Stem Cell Transplantation | |
haplo-HSCT | |
haploidentical donor | |
haploidentical hematopoietic stem cell transplantation | |
Haploidentical HSCT | |
haploidentical stem cell transplantation | |
Haplotype | |
Haplotype frequencies | |
haplotype frequency | |
haplotype loss | |
Haplotypes | |
HCV | |
healthy ageing | |
heart transplantation | |
heart valvular prosthesis | |
Hematological malignancies | |
Hematopoeitic Stem Cell Transplantation | |
hematopoietic cell transplantation | |
Hematopoietic stem cell tranplantation | |
hematopoietic stem cell transplantation | |
Hematopoietic stem cells | |
hematopoietic-specific TCRs | |
herpesviruses | |
HIBAG | |
High dimensional flow cytometry | |
High resolution | |
high-resolution | |
Highly Sensitized Candidates | |
histocompatibility | |
HLA | |
HLA allele | |
HLA allele distribution | |
HLA alleles | |
HLA antibodies | |
HLA antigens | |
HLA association study | |
HLA class I | |
HLA class I alleles | |
HLA class I expression | |
HLA class II | |
HLA class II-knockout | |
HLA class-I | |
HLA Crossmatch | |
HLA diversity | |
HLA DPB1* antibodies | |
HLA DPB1* typing | |
hla epitopes | |
HLA expression | |
HLA frequencies | |
HLA frequency | |
HLA genes | |
HLA genotyping | |
HLA haplotypes | |
HLA homozygous donor | |
HLA immunization | |
HLA imputation | |
HLA incompatible | |
HLA loss relaps | |
HLA loss relapse | |
HLA matching | |
HLA mismatch | |
HLA mismatches | |
HLA molecular diversity | |
HLA Monoclonal Antibody | |
HLA polymorphism | |
HLA sensitization | |
HLA serological specificities | |
HLA staff | |
HLA typing | |
HLA-B | |
HLA-B*35 | |
HLA-B*35:435:02 | |
HLA-C | |
HLA-Containing Exosomes | |
HLA-DM | |
HLA-DM-meditated peptide editing | |
HLA-DO | |
HLA-DP | |
HLA-DP immunopeptidome | |
HLA-DPB1 | |
HLA-DPB1 matching | |
HLA-DQ | |
HLA-DQA1 | |
HLA-DQB1*02 | |
HLA-DQB1*08 | |
HLA-DR | |
HLA-DR negative myeloid cells | |
HLA-DRA | |
HLA-DRB1 | |
HLA-F | |
HLA-G | |
HLA-G polymorphisms | |
HLA-H | |
HLA-I alterations | |
HLA-Matchmaker | |
HLA-mediated drug hypersensitivity | |
HLA-mismatch | |
HLAMatchmaker | |
HNA | |
homozygosity | |
hospitalization | |
HPA | |
hsa-miR-20a | |
hsa-miR-92b | |
HSC transplant | |
HSCT | |
HSCT - Hematopoietic Stem Cell Transplantation | |
HSCT transplantation | |
HSCT-Hematopoietic stem cell transplantation | |
HSCT: Hematopoietic Stem Cell Transplantation | |
Human | |
Human and chimpanzee comparative genetics | |
Human cytomegalovirus | |
Human evolution | |
Human Leucocyte Antigene H | |
Human Leukocyte Antigen | |
Human Neutrophil Antibodies | |
Humoral immunity | |
humoral rejection | |
Hybrid capture | |
Hypersensitivity reactions | |
I | |
IgG Subtypes | |
IL-5 IL-9 and IL-13 genes | |
Illumina | |
ILT-2 | |
imaging mass cytometry | |
imatinib | |
immune cell | |
Immune cell profiling | |
Immune Cells | |
immune checkpoint | |
Immune deficiency | |
immune pathways | |
immune reconstitution | |
Immune repertoire | |
Immune Thrombocytopenic Purpura | |
Immune-mediated rejection | |
Immunity | |
immunochekpoints | |
Immunoediting | |
immunogenetics | |
Immunogenetics population | |
immunogenicity | |
Immunogentics of SARS-CoV-2 | |
immunoglobulin | |
immunology | |
Immunomodulation | |
Immunopeptidome | |
immunopeptidomes | |
immunophenotyping | |
Immunoprotection | |
immunoregulation | |
Immunosequencing | |
immunosuppression | |
immunotherapy | |
Implementation | |
Imputation | |
Inclusiveness | |
indel analysis | |
induction immunosuppression | |
induction therapy | |
Infection | |
Inflammatory bowel disease | |
Influence | |
Interspersed genomic repeats | |
Intron sequences | |
Invasive pneumococcal diseases (IPDs) | |
iSeq | |
Isolation T and B cells | |
Israel | |
ITP | |
J | |
Japanese | |
Jon van Rood | |
Journal | |
Julia | |
K | |
Kell | |
Kidney | |
Kidney Transplant | |
Kidney transplantation | |
killer cell immunoglobulin-like receptor | |
Killer Immunoglobulin-like Receptors (KIR) | |
killer-cell immunoglobulin-like receptor | |
killer-cell Immunoglobulin-like receptor (KIR) | |
KIR | |
KIR/HLA interactions | |
KIR3DL1/S1 | |
Knockout | |
L | |
Labscreen | |
LAIR | |
Landsteiner-Wiener | |
Lecture | |
Leukemia | |
Lewis | |
Ligands of NK cell receptors | |
LILR | |
LIMS | |
Linkage disequilibrium | |
Liquid Handler | |
Liver | |
Liver transplant | |
long non coding RNA | |
long short-term memory (LSTM) | |
long-read sequencing | |
Loss of Heterocigosity | |
Loss of heterozigosity (LOH) | |
Loss of heterozygosity | |
LRC | |
Luminex | |
Luminex screening test | |
Luminex Single Antigen (LSA) | |
Luminex-beads | |
lung transplant | |
Lung transplantation | |
Lymphocytes | |
Lymphoma | |
M | |
Macaques | |
machine learning | |
Macrophages | |
Magic | |
Major histocompatibility complex | |
Major histocompatibility complex (MHC) | |
Matched Unrelated Haematopoietic Stem Cell Transplantation | |
matched unrelated stem cell donor | |
Matching | |
Maternal-fetal interface | |
MaxPrep | |
Maxwell | |
mean fluorescence intensity | |
memory B cells | |
menstrual blood | |
menstrual cycle | |
Mesenchymal Stem Cells | |
Mesenchymal Stromal Cells | |
Mesencyhmal Stem Cells | |
Method development | |
MFI | |
MHC | |
MHC class I A evolution | |
MHC evolution | |
MHC homozygous haplotype | |
MHC-DQB | |
MICA | |
MICB | |
microbiota | |
Microfluidic | |
microRNA | |
MIF | |
minimal typing requirements | |
minor histocompatibility antigens | |
minor histocomptibility antigens | |
miRNA | |
miRNA PCR array | |
MiSeq | |
Mismatched | |
mismatches | |
Monoclonal antibodies therapy | |
monoclonal antibody | |
monocytes | |
Morocco | |
Mortality | |
mother-child pairs | |
MPN | |
MRI | |
mTOR | |
Multi-region | |
Multiple sclerosis | |
multiplex | |
Multiplex based HLA typing | |
Multiplex dPCR | |
Multiplex NGS | |
Myasthenia Gravis | |
myeloid | |
myeloproliferative neoplasms | |
N | |
Nanopore sequencing | |
natural killer cell | |
Natural Killer Cells | |
Necrotizing myopathy | |
neo-epitopes | |
neurological disease | |
Neuromyelitis optica | |
New allele | |
New Alleles | |
New Technolgies | |
next generation sequencing | |
Next-Generation Sequencing | |
NGS | |
NGS based genotyping | |
NGS long read | |
NGS sequencing | |
NGS typing | |
NGS: Next Generation Sequencing | |
NK alloreactivity | |
NK cell | |
NK cell receptors | |
NK cells | |
NKG2D | |
Nodding Syndrome | |
non classical HLAII | |
non-classical HLA genes | |
Non-HLA | |
nonHLA | |
North-West region of Russia | |
Novel allele | |
Novel Alleles | |
NPM1 mutation A/D | |
Nucleophosmin | |
O | |
oocyte donation | |
Open Science | |
Optimization | |
organ allocation | |
organ donor | |
Organoids | |
Outcome | |
overal and cancer-specific survival | |
Oxford Nanopore sequencing | |
P | |
PacBio | |
Pacbio sequencing | |
PacBio SMRT Sequencing | |
Paediatric patients | |
Paediatrics heart transplantation | |
Pandemic | |
pathway | |
Patient outcome | |
patient survival | |
Patr genes | |
PCR array | |
PCR-SSP | |
PD-L1 expression | |
Pediatric disease | |
pemphigus | |
peptide binding motifs | |
Peptide binding prediction | |
Peptide editing | |
peptide editor | |
peptide repertoires | |
peptide-binding groove polymorphism | |
Permissible mismatch | |
permissive mismatches | |
Permissiveness | |
permissiveness of HLA mismatch | |
Personalized Immunotherapy | |
personalized medicine | |
Pharmacogenetics | |
Phasing | |
PIRCHE | |
placenta | |
placental pathology | |
Plasma Exchange | |
Platelet | |
Polymorphism | |
Population coverage | |
Population Genetics | |
Population reference graph (PRG) | |
Population Study | |
post hematopoietic stem cell transplantation | |
Post-transplant antibodies | |
Post-transplant lymphoproliferative disease (PTLD) | |
Poster | |
PRA (panel-reactive antibody) | |
pre-existing tissue-resident memory | |
pre-transplant risk assessment | |
Prediction | |
pregnancy | |
primary tumors | |
Primates | |
PROCARE Consortium | |
Profiling | |
Promega | |
Pronase | |
Proteome | |
psoriasis vulgaris | |
psoriatic arthritis | |
Q | |
QIAcuity Digital PCR System | |
R | |
RAET1E | |
Rare alleles | |
rare allleles | |
Rare disease | |
RAS | |
Reactive programming | |
Real-time PCR | |
receptors | |
recombinant HLA | |
Recurrent Pregnancy Loss | |
Reference cell lines | |
reference panel | |
reflex beads | |
Regenerative medicine | |
REGULATION | |
Regulatory B cells | |
Regulatory T cells | |
rejection | |
related HLA identical donor | |
Remarks | |
renal | |
Renal Transplantation | |
Research evaluation | |
Resolution of Ambiguities | |
resolving not yet known sequences | |
Rhesus macaques | |
Rheumatoid Arthritis | |
RNA-Seq | |
Robotics | |
RPL | |
RPL with subsequent ongoing pregnancy | |
S | |
sacroiliitis | |
Sample throughput | |
sarcoma | |
Sars-Cov | |
SARS-CoV-2 | |
SARS-CoV2 | |
SARSCoV2 | |
second transplantation | |
sensitivity | |
Sensitization | |
Sensitized Patients | |
sensitizing event | |
sensitizing events | |
Sequences | |
Sequencing | |
Session | |
severity | |
Shiny | |
SHLARC | |
short-read sequencing | |
simulation | |
Simultaneous Liver-Kidney Transplantation | |
Single Antigen Bead Assay | |
Single cell RNA sequencing | |
Single Nucleotide Polymorphism | |
Single Nucleotide Polymorphisms (SNPs) | |
Single-cell RNA sequencing | |
single-nucleotide polymorphism analysis | |
SIRP | |
Site-Directed Mutagenesis | |
skin disease | |
small-scale | |
Software | |
solid organ | |
solid organ transplant | |
Solid Organ Transplantation | |
Solid-phase assays | |
Soluble HLA | |
Soluble HLA-G | |
Somatic mutations | |
splice site mutation | |
Statistics | |
Stem cell | |
Stem Cell Registry | |
Stem cell transplantation | |
STR | |
Stromal reaction | |
structural variation | |
Survey | |
Survival | |
Survival Analysis | |
synovitis | |
T | |
T Cell | |
T cell epitopes | |
T cell receptor | |
t cell rejection | |
T cell responses | |
T cells | |
T-cell | |
T-cell alloreactivity | |
T-cell cross-reactivity | |
T-cell epitopes | |
T-cell receptor (TCR) repertoire | |
T-Memory | |
T-naive | |
T1D | |
TCE algorithm | |
TCR repertoire analysis | |
TCR: T Cell Receptor | |
telomerase reverse transcriptase (TERT) | |
telomere length | |
TERT polymorphic variants | |
TGS | |
Th2 cytokine polymorphisms | |
THP-1 | |
Thymus | |
tissue chimerism | |
TNFA | |
tocilizumab | |
Tolerance | |
transcription factor | |
transcytosis | |
transfusion | |
Transplant | |
Transplant algorithm | |
Transplant vasculopathy | |
transplant-reated mortality | |
Transplantability score | |
Transplantation | |
Transposable elements | |
Treg | |
trophoblast | |
Trophoblast interactions | |
tumor grade | |
tumor microenvironment | |
Tumor-Associated Antigens | |
tumor-derived exosomes | |
Turn around time | |
type 1 diabetes mellitus | |
Type-1-Diabetes Mellitus | |
typing | |
U | |
ULBP4 | |
UMAP | |
Umbilical Cord Blood | |
Umbilical Cord Tissue (Wharton’s Jelly) | |
undifferentiated spondyloarthritis | |
unrelated donor | |
Unrelated donors | |
Unrelated Haematopoietic Stem Cell Transplantation | |
V | |
Vaccination | |
Vaccine | |
Varicella zoster virus | |
VDR polymorphism | |
Vel | |
very rare alleles | |
W | |
waiting list | |
Waiting lists | |
Website | |
Welcome | |
Well Defined alleles | |
Whole exome sequencing | |
Whole genome sequence | |
Whole genome sequencing | |
Work flow assessment | |
Workflows | |
X | |
Xenotransplantation | |
α | |
αβ T cells | |
γ | |
γδ T cells | |
γδT cells |